Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to ...
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...
July 20 (Reuters) - Tempus AI said on Monday it would buy Personalis in an all-stock deal valued at about $1.5 billion, adding a cancer test to the AI-enabled precision medicine firm's oncology ...
Preview this article 1 min Personalis shareholders will receive $16.25 per share. The deal is expected to close in late 2026 ...
Tempus AI has agreed to acquire the cancer genomics company Personalis in a deal valued at about $1.5 billion, the companies announced July 20. The acquisition builds on a partnership the two ...
On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
X is making it easier for AI assistants like Claude, Cursor, Grok Build, and other MCP-compatible apps to connect directly to the platform through a new hosted MCP server. On Monday, the Elon ...
Tempus AI, Inc. TEM announced on Monday a definitive agreement to acquire Personalis, Inc. PSNL, aiming to advance cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results